Company news
Arvinas, Inc. news in 2021
Arvinas, Inc.'s news releases, calls and decks from 2021, newest first.
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
December 9, 2021
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
November 18, 2021
Arvinas to Present at Stifel 2021 Virtual Healthcare Conference
November 9, 2021
Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 2, 2021
Arvinas to Participate in Upcoming Virtual Investor Conferences
August 31, 2021
Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 4, 2021
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
July 21, 2021
Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven
June 6, 2021
Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference
June 2, 2021
Arvinas to Present at the UBS Global Healthcare Virtual Conference
May 19, 2021
Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven
May 3, 2021
Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 3, 2021
Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
April 4, 2021
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
February 28, 2021
Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day
February 7, 2021
Decks in 2021
- San Antonio Breast Cancer Symposium 2021
Conference · 16 slides · Dec 10, 2021